Clinical Trial

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

Study acronym: cosMOG
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
Protocol Amendment History 1 change
notable Trial sites reduced: 73 -> 55 locations 2026-05-23
Trial Details
NCT Number NCT05063162
Lead Sponsor UCB Biopharma SRL
Conditions Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Enrollment 113 participants
Start Date 2022-02-02
Primary Completion 2027-05-06 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14